| 摘要 |
<p>The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5- HT1B , 5- HT1D and 5- HT1F receptors, such as a triptan , e.g. zolmitriptan , in a matrix constituent with extended release characteristics , and further comprising a 5 -HT1A- R agonist , such as buspirone , in a constituent with immediate release characteristics. The special formulation is particularly well -suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation , allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.</p> |
